Progyny (NASDAQ:PGNY) Downgraded by Wall Street Zen to “Hold”

Wall Street Zen cut shares of Progyny (NASDAQ:PGNY) from a buy rating to a hold rating in a report published on Saturday.

A number of other analysts also recently weighed in on PGNY. Weiss Ratings reiterated a “hold (c)” rating on shares of Progyny in a research report on Friday, March 27th. Canaccord Genuity Group lowered their target price on shares of Progyny from $26.00 to $19.00 and set a “hold” rating for the company in a research note on Wednesday, March 11th. Truist Financial cut their target price on shares of Progyny from $34.00 to $28.00 and set a “buy” rating on the stock in a report on Monday, March 2nd. Citigroup raised shares of Progyny to an “outperform” rating in a research report on Tuesday, January 20th. Finally, Citizens Jmp raised shares of Progyny from a “market perform” rating to an “outperform” rating and set a $30.00 price target for the company in a report on Tuesday, January 20th. Nine research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $27.91.

Progyny Price Performance

Shares of Progyny stock opened at $16.60 on Friday. The business has a fifty day simple moving average of $19.77 and a 200 day simple moving average of $22.17. The stock has a market cap of $1.30 billion, a PE ratio of 25.54, a price-to-earnings-growth ratio of 0.96 and a beta of 0.99. Progyny has a 12 month low of $16.28 and a 12 month high of $28.75.

Progyny (NASDAQ:PGNY) last released its earnings results on Thursday, February 26th. The company reported $0.48 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.10. Progyny had a return on equity of 11.37% and a net margin of 4.54%.The firm had revenue of $318.40 million for the quarter, compared to analyst estimates of $314.26 million. During the same quarter in the prior year, the firm posted $0.42 earnings per share. The company’s quarterly revenue was up 6.7% on a year-over-year basis. Progyny has set its FY 2026 guidance at 1.830-1.950 EPS and its Q1 2026 guidance at 0.420-0.450 EPS. Analysts expect that Progyny will post 0.6 EPS for the current fiscal year.

Insider Activity

In related news, EVP Allison Swartz sold 4,657 shares of the business’s stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $17.40, for a total value of $81,031.80. Following the completion of the transaction, the executive vice president directly owned 89,879 shares in the company, valued at approximately $1,563,894.60. The trade was a 4.93% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last three months, insiders sold 7,455 shares of company stock valued at $129,515. 9.40% of the stock is currently owned by insiders.

Institutional Trading of Progyny

Several hedge funds have recently bought and sold shares of PGNY. Wellington Management Group LLP boosted its holdings in shares of Progyny by 260.9% in the fourth quarter. Wellington Management Group LLP now owns 2,243,268 shares of the company’s stock valued at $57,607,000 after buying an additional 1,621,688 shares during the period. Loomis Sayles & Co. L P acquired a new stake in shares of Progyny during the fourth quarter worth $19,917,000. Barclays PLC lifted its position in Progyny by 79.2% in the 3rd quarter. Barclays PLC now owns 1,575,470 shares of the company’s stock valued at $33,904,000 after acquiring an additional 696,447 shares in the last quarter. Ameriprise Financial Inc. lifted its position in Progyny by 37.6% in the 2nd quarter. Ameriprise Financial Inc. now owns 1,996,957 shares of the company’s stock valued at $43,933,000 after acquiring an additional 545,431 shares in the last quarter. Finally, Nomura Holdings Inc. acquired a new position in Progyny in the 2nd quarter worth $9,368,000. 94.93% of the stock is currently owned by institutional investors and hedge funds.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.